Trials / Completed
CompletedNCT00733304
An Extension to Study MD7108240
An Extension Study to Protocol MD7108240: Pazopanib Eye Drops in Subjects With Neovascular Age-related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a two month study to allow continued treatment with pazopanib eye drops. Study may be extended to 5 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pazopanib | 5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD |
Timeline
- Start date
- 2008-06-25
- Primary completion
- 2009-09-09
- Completion
- 2009-09-09
- First posted
- 2008-08-13
- Last updated
- 2017-12-05
- Results posted
- 2017-12-05
Locations
17 sites across 3 countries: United States, Australia, Italy
Source: ClinicalTrials.gov record NCT00733304. Inclusion in this directory is not an endorsement.